NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5th, at the JW Marriott Orlando Grande Lakes, Orlando, FL. Ahmet Tezel, Company Group Chairman, MedTech R&D will represent the Company in a session scheduled at 2:15 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. ...

股市波动与投资建议 - 长期投资者应该对股市的波动保持耐心，因为每次市场调整、崩盘和熊市最终都会被牛市的反弹所抹去[1] - S&P 500指数在短期内表现难以预测，但最近已经创下历史新高，可以确定我们正处于牛市中[2] 退休人士投资建议 - 退休人士可以在新牛市中大胆购买Visa、Johnson & Johnson和AT&T这三只股票[5]

专利悬崖问题 - 引发药企关注的专利悬崖问题，即多款明星药品专利即将到期，面临销售额大幅下滑的风险[2][3][4] - 部分药企通过建立药品管道、进行收购或与其他公司合作来抵消即将到来的专利悬崖带来的损失[4][5] - 针对即将失去专利保护的一些热门药品，包括默沙东的Keytruda、百时美施贵宝的Eliquis和强生的Stelara，预计未来销售额将大幅下降[9][10][11][12][13] 生物类似药物 - 生物类似药物（biosimilars）对品牌生物药物的市场份额威胁有限，与小分子药物的仿制药相比，生物类似药物更难获得市场份额[16][17] 延长市场独占期 - 部分药企通过推出更便捷的药品版本、延长专利保护或与竞争对手达成和解来延长药品的市场独占期[37][40][41] 药价谈判影响 - 联邦政府将对一些药品进行药价谈判，可能会影响药企的收入，但具体影响取决于药品失去独家权的时间[44][45][48][49]

公司背景 - 强生公司是一家成立于1886年的跨国公司，总部位于美国新泽西州纽布朗斯维克市，主要经营医疗保健和制药业务[2] - 强生公司在制药行业的地位在2022年基于药品收入排名中处于领先地位[4] - 尽管销售额排名第三，但强生公司在研发方面的支出排名第二，显示出公司在研发方面的投入和潜力[5] 药品研发与批准 - 强生公司的一款关键药物Balversa获得FDA批准，这将有助于提高销售增长并减少公司整体风险[6] - 强生公司的新举措和FDA批准的关键药物表明公司未来前景乐观，建议购买[25] 财务表现与展望 - 过去几年，强生公司的营业额和利润出现了显著波动，主要受到COVID-19疫情的影响[7] - 根据最近的财报显示，强生公司的销售额在过去一年增长了6.5%，预计未来几年销售增长率将继续保持在7%左右[8] - 强生公司的自由现金流在2023年出现了明显下降，这可能是由于销售额减少和研发支出增加所致[13] 风险与挑战 - 尽管面临来自塑料粉末相关诉讼的风险，但强生公司通过多元化业务和积极应对措施来减轻潜在影响[16] 股价估值 - 经过DCF估值，预计强生公司的股价目标为188.33美元，具有16.48%的上涨空间[24]

UnitedHealth Group (UNH 1.99%) and Johnson & Johnson (JNJ -0.04%) are two of the largest healthcare companies in the world. One is focused on health insurance, while the other makes medical devices and pharmaceuticals. They both pay dividends and have generated good returns for investors over the years. But which one is the best option for growth-oriented investors today?UnitedHealth's endless pursuit of acquisitions could make it an underrated growth investmentA health insurance company may not attract man ...

Investing in the stock market isn’t without the risks, but what if you could generate extra income from your investment? If you are a risk-averse investor like me and want to build a retirement portfolio, dividend stocks with consistent cash flow will appeal to you. You can achieve your goal of generating consistent income while you enjoy capital appreciation. If you invest in the right stocks, you can also cover expenses throughout the year. With the ongoing earnings season, several companies will hike the ...

分组1 - 美国参议员伯尼·桑德斯宣布默克和强生公司的CEO自愿同意在即将举行的参议院听证会上作证[2] - 参议院卫生、教育、劳工和养老金委员会的听证会定于东部时间2月8日上午10点举行，委员会计划要求J&J CEO Joaquin Duato和默克CEO Robert Davis作证[3] - 委员会将要求每位执行官就为何他们的公司在美国收取的药品价格远高于其他国家提供证词[5] - 三家公司生产的一些最昂贵的药物将受到第一轮医疗保险药品价格谈判的影响[6] - 三家公司都在起诉以阻止这些谈判，这些谈判将确定2026年生效的新价格[7] - 桑德斯希望这些制药公司的CEO能认真审视这些令人难以置信的价格差异，并与委员会合作，大幅降低他们向美国人收取这些和其他处方药的价格[8] 分组2 - 默克发言人表示相信这将是一次有益的听证会，旨在增进委员会对制药行业的理解，并找到面向患者挑战的常识性解决方案[9] - 委员会拒绝了公司提出的让其美国总裁作为证人的建议，认为CEO更适合回答有关药品定价的问题[10] - 强生公司尚未对置评请求做出回应[11]

Johnson & Johnson (JNJ) reported fourth-quarter and full-year 2024 results on Jan 23. The drug and medical devices giant beat the Zacks Consensus Estimate for both earnings as well as sales in the fourth quarter.In August, J&J completely separated its Consumer Health business into a newly listed company called Kenvue (KVUE) , which now operates as a separate and fully independent company.After completion of the exchange offer, J&J now has a 9.5% stake (approximately 180 million shares) in Kenvue’s common st ...

Buying dividend-paying stocks to hold for long periods is a relatively simple method for building wealth. That said, picking stocks most likely to maintain and raise their dividend payouts isn't always so straightforward.Johnson & Johnson (JNJ -0.53%) and Verizon Communications (VZ -2.25%) are two legendary dividend payers that recently announced results from the last three months of 2023. Let's look at their performances in light of their competitive advantages to see which is likely to deliver more divide ...

One of the best ways to create wealth is finding the right dividend stocks to buy and hold. No other asset class has performed as well as buying equities, not gold, not bonds, not real estate. Several years ago Deutsche Bank (NYSE:DB) published a study showing that over the past century, stocks beat out gold by 5.6% per year, housing prices by 6.6%, Treasuries by 6.8%, and oil by 8.4% per year.And among the best stocks to buy have been dividend stocks. Over the past 100 years, they’ve outperformed non-divid ...